Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
169
resultados
Última actualización
29/10/2026 [07:08:00]
Resumen de: US20250195761A1
0000 Systems and methods are provided for sending a software update to an insulin pump and/or user device used with the insulin pump and selectively enabling and disabling certain functionality (e.g., operations, tasks, functions, and/or features) enabled by the software update and/or settings adjusted by the software update. The software update may be in the form of a software package that is sent from a remote device to all insulin pumps or user devices on an insulin pump network. While all devices may receive the same software update it may be desirable to restrict certain functionality and/or settings for some insulin pumps and/or user devices. The insulin pump, user device associated with the insulin pump, and/or remote device in communication with the user device, may determine whether the functionality in the software update should be disabled or otherwise not enabled for a certain insulin pump and/or user device.
Resumen de: WO2025137203A1
The present invention relates generally to systems, devices, and methods for in vivo monitoring of an analyte level. In particular, the present invention relates to sensors having saccharides or similar molecules present in glucose-oxidase containing sensing layers to improve sensor stability.
Resumen de: EP4830625A1
0001 A glucagon patch pump designed for managing glucose levels in individuals, particularly those with diabetes. The glucagon patch pump includes a base that attaches to a patient's tissue site, a medication bladder for storing glucagon, a medication pump with a conduit for delivering the medication, and a cannula insertion device that deploys the cannula when glucose levels fall below a predetermined threshold. The system can automatically administer glucagon in response to low glucose levels, reducing the need for second-party intervention and minimizing the risk of prolonged hypoglycemia. The glucagon patch pump can be part of a comprehensive glucose management system that includes a glucose sensor and a processor to monitor and respond to glucose levels.
Resumen de: US20260325585A1
Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.
Resumen de: US20260325852A1
The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal/cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.
Resumen de: AU2026242160A1
The present disclosure relates to compositions and methods for treating liver cancers, especially hepatocellular carcinoma, using antisense (AS) nucleic acids directed against Insulin- like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of liver cancer. ep e p
Resumen de: US20260325752A1
0000 Techniques disclosed herein relate to infusion devices and related meal bolus adjustment methods. In some embodiments, the techniques may involve determining an initial bolus amount to compensate for food consumption. The techniques may further involve predicting an initial value for a physiological condition based at least in part on the initial bolus amount and one or more insulin deliveries. The techniques may further involve identifying an adjusted bolus amount based on the predicted value. The techniques may further involve causing delivery of the adjusted bolus amount.
Resumen de: AU2025254093A1
Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.
Resumen de: AU2025255066A1
The present invention relates to a cytidine diphosphocholine glycoside represented by general formula (1), a salt thereof, an N-oxide thereof, a solvate thereof, or the like. (In formula (1), R is a sugar residue.)
Resumen de: AU2025249757A1
A variability metric of glucose level values of a user is calculated for each candidate sleeping time frame in a data set of glucose level values of the user obtained over time for a specified period for each day of multiple days. Each of the candidate sleeping time frames may represent a duration in which the user may have been sleeping. Execution of the programming instructions further may cause the processor to determine a mean or median of the variability metric of the glucose level values in the data set for each candidate sleeping time frame across the days in the specified period, designate a selected one of the candidate sleeping time frames that has the lowest mean or median variability metric as the sleeping time frame, and configure the pump to deliver a sleeping basal rate of the medicament for the designated sleeping time frame.
Resumen de: US20260325016A1
0000 Provided are a blood glucose management system using a continuous glucose monitor and a method therefor. The blood glucose management system may include a data collector configured to collect blood glucose data measured through a continuous glucose monitor worn by a patient; a data analyzer configured to analyze the collected blood glucose data to calculate values of a plurality of blood glucose variables representing a blood glucose state of the patient; and a data provider configured to provide the values of the blood glucose variables through a monitoring board. By using the system, the blood glucose states of patients can be thoroughly monitored and managed.
Resumen de: US20260325015A1
0000 A method for noninvasive continuous glucose monitoring (CGM) using bandpass Raman spectroscopy (BRS) includes: irradiating, by a light source, light to a subject; detecting, by a photodetector, the light that is reflected from the subject; obtaining intensities of peaks at one or more predetermined Raman bands in a Raman spectrum occurring due to Raman shift, wherein the one or more predetermined Raman bands include a glucose Raman peak and two sidebands; and obtaining at least one glucose metric based on the intensities of peaks at the one or more predetermined Raman bands. The glucose metric is an area metric and/or a slope metric. Based thereon, a glucose level associated with the subject is determined.
Resumen de: WO2026221010A1
The present disclosure provides a method for identifying a treatment that promotes differentiation of a first cell into a second cell. The present disclosure also provides pancreatic beta cells or cells that are capable of differentiating into pancreatic beta cells. In the present disclosure, the pancreatic beta cells or cells that are capable of differentiating into pancreatic beta cells have a deletion of a specific gene, whereby the same preferably exhibit a high capability of differentiating into pancreatic beta cells, or exhibit a capability of differentiating into pancreatic beta cells exhibiting a glucose-dependent C-peptide secretion ability.
Resumen de: US20260325017A1
0000 Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.
Resumen de: US20260325083A1
A lens-type medical detection device includes a SoC connected to a display, a communication module, a remote measurement module, and a fall detection module. The communication module establishes connection with a cloud server and a contact person. The cloud server includes an artificial intelligence model. A light-emitting unit illuminates a subject and a lens successively captures multiple images, each of which is transmitted to the cloud server to be subjected to computation performed by the artificial intelligence model to generate physiological information, which is transmitted back and outputted to the display. The physiological information includes heartbeat, heart rate, blood pressure, blood oxygen, blood sugar, and lactic acid. Based on the physiological information, the artificial intelligence model generates a comprehensive health assessment for prompting proper handling to the subject and the family. The fall detection module detects a fall of the subject and notifies a contact person through the communication module.
Resumen de: AU2026242121A1
Recommendations based on continuous glucose monitoring (CGM) are described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform processes these measurements and the additional data to predict a health indicator by using models. This prediction serves as a basis for generating a recommendation, such as a message recommending the user take action or adopt a behavior to mitigate a predicted negative health condition. ep e p
Resumen de: US20260325753A1
0000 The exemplary embodiments may provide a secure framework for devices in a drug delivery system to wirelessly communicate. The secure framework may use encrypted keys to carry credentials and to specify the rights of the devices presenting the credentials. The devices in the drug delivery system present the keys at the time that they wish to wirelessly communicate with other devices in the drug delivery system. The devices receiving such keys, decrypt the keys and verify if the credentials are valid. If the credentials are valid, a wireless communication session between devices may be established.
Resumen de: US20260325582A1
0000 The purpose of the present invention is to provide a novel therapeutic agent for renal disease. The present invention is a therapeutic agent for renal disease containing a mesenchymal stem cell culture supernatant. The mesenchymal stem cell culture supernatant is preferably a culture supernatant obtained from the cultivation of mesenchymal stem cells derived from adipose tissue, umbilical tissue, or bone marrow tissue. In addition, the mesenchymal stem cell culture supernatant is preferably obtained from the cultivation of mesenchymal stem cells in a culture medium containing at least one substance selected from the group consisting of EGF, bFGF, albumin, transferrin, and insulin.
Resumen de: US20260327567A1
0000 Provided are a cell culture product and the use thereof. The cell culture product comprises a hepatic progenitor cell proliferation medium, containing a DMEM/F12 medium, insulin, transferrin, sodium selenite, nicotinamide, 2-phosphate-L-ascorbic acid, a human recombinant albumin, an epidermal cell growth factor, a glycogen synthase kinase 3 inhibitor, a transforming growth factor β receptor inhibitor, lysophosphatidic acid, and sphingosine phosphate.
Resumen de: WO2025128082A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Resumen de: AU2015325028A1
Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.
Resumen de: US20260314958A1
0000 The present invention proposes a method of measuring the real-time level and degree of management of blood sugar based on an electrocardiogram. The method includes: obtaining an electrocardiogram signal measured for a user; estimating the user's blood sugar level by analyzing the electrocardiogram signal using a pre-trained first artificial intelligence, and determining whether the user has hyperglycemia or hypoglycemia by analyzing the electrocardiogram signal using an artificial intelligence; and determining whether the user needs guidance on blood sugar or diabetes based on the estimated blood sugar level and the result of the determination of whether the user has hyperglycemia or hypoglycemia. Through this, a user may check the user's immediate blood sugar level and how well the blood sugar is managed simply by measuring the electrocardiogram 10, and as a result, hyperglycemia and diabetes may be detected early or a complication attributable to hyperglycemia or diabetes may be prevented.
Resumen de: US20260315694A1
0000 Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
Resumen de: AU2026242095A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes 5 and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein. ep e p
Nº publicación: US20260315755A1 15/10/2026
Solicitante:
NEUROTRONIC INC [US]
Neurotronic, Inc.
Resumen de: US20260315755A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
BOPI
Sede Electrónica
